🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Highlight: En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial buff.ly/46zlBES #UroSoMe #Medtwitter

A big day for bladder ca patients U.S. FDA. Massive team effort. Platinum based chemo superseded at last. EV/pembro will transform the lives of many pts with this difficult disease. Still lots to do but it’s a pretty good day and worth pausing for a moment. bit.ly/3GLntQn

Best EAU guidelines 🇪🇺 crew with a magnificent view! Thank you Association Française d'Urologie - AFU 🇫🇷for this incredible night in hôtel de Crillon. Prof Param Mariappan FRCS(Urol), PhD Paolo Gontero francesco soria

Impressive results presented by Joe Jacob MD, MCR at #AUA2024 from SunRISE-1 trial showing 82.8% CR rate at anytime and 12mo DOR 74.6%. Well tolerated. Andrea Necchi Hussein Sweiti, MD IBCG Bladder Cancer Advocacy Network

Good day for #bladdercancer BOND-3 results presented by Mark Tyson showing 75.2% CR at anytime for pts with BCG unresponsive disease. Over half of non responders converted to CR with repeat dosing. 96.7% PFS@12 mos. More trials to come through Society of Urologic Oncology Roger Li CG Oncology, Inc.

A great honor today for our family at MolinetteUrology to have Prof. David Penson Dave Penson with us in Turin! 🇮🇹🇺🇸 Paolo Gontero umberto ricardi Prof.Albera Prof.ssa Cassoni Giancarlo Marra Marco Oderda francesco soria Marco Calandri AOU CittàdellaSalute Università di Torino Amer. Urol. Assn. Vanderbilt Health

Perhaps the most important long-term bladder cancer data #ASCO24 Neoadjuvant Toripalimab & disitimab Vedotin in muscle invasive bladder cancer (n=47). pCR ⬆️ 63%. 14% G3/4 AEs. All surgeries occurred . The 1st MMAE/IO neoadjuvant combo data looks ✅✅. EV/IO MIBC trials awaited

Clinical Validation of the Intermediate-risk NMIBC Scoring System and Substratification Model Proposed by the IBCG (International Bladder Cancer Group): A Multicenter YAU Urothelial Working Group Collaboration European Urology Oncology Paolo Gontero francesco soria authors.elsevier.com/c/1jIAG9Cfv--d… a🧵

Video in UroToday.com: francesco soria discusses a study validating the @IBCG scoring system for intermediate-risk bladder cancer with Ashish M. Kamat, MD, MBBS: urotoday.com/video-lectures…

Happy to share the link to the newly released summary of the NMIBC EAU guidelines! kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2… Thanks to European Association of Urology (EAU) EAU guidelines Maria J. Ribal for support and to Alex Masson-Lecomte Emma Jane Smith Prof Param Mariappan Shahrokh F. Shariat for the outstanding work!

🎥 francesco soria and Ashish M. Kamat, MD, MBBS discuss validating the IBCG scoring system for IR #BladderCancer, showing significant differences in recurrence and progression rates, and suggesting tailored treatments, impacting practice and guidelines. #WatchNow > bit.ly/3yRu7o0

Urothelial Cancer Update 2024 🔬📍27 th of September 2024 - Turin. 📝 Registration for residents is free! Don't miss the opportunity to join this 1 day multidisciplinar update meeting 🔮 Waiting for you in Torino! Paolo Gontero francesco soria Società Italiana di Urologia Università di Torino AOU CittàdellaSalute

Let’ s start a super interesting meeting on urothelial cancer update organized by Paolo Gontero francesco soria Superb tips & tricks on en bloc resection of bladder tumour by Jeremy Teoh 👏🏼👏🏼👏🏼

Some highlights from Urothelial Cancer Update 2024 Congress Paolo Gontero francesco soria Università di Torino AOU CittàdellaSalute ⤵️

🎥 francesco soria and Ashish M. Kamat, MD, MBBS discuss validating the IBCG scoring system for IR #BladderCancer, showing significant differences in recurrence and progression rates, and suggesting tailored treatments, impacting practice and guidelines. #WatchNow > bit.ly/3yRu7o0

🎧 Ascoltalo su tutte le piattaforme podcast! 👨‍⚕️👩‍⚕️ Fotios Loupakis, medico oncologo, e Aureliano Stingi PhD, biologo molecolare, incontrano gli urologi francesco soria e Francesco Esperto, l’oncologo Luigi Formisano e l’oncologa Patrizia Giannatempo per discutere sulle diverse fasi del tumore

Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group by francesco soria et al buff.ly/3Bg84Zj #UroSoMe #MedTwitter #EUO

European Urology Oncology francesco soria Great to see the multicenter validation of the IR NMIBC Scoring System, originally proposed by IBCG (IBCG) in 2014 and refined in 2022 Kudos to francesco soria Paolo Gontero et al Joan Palou Redorta Gary Steinberg Maria J. Ribal Wei Shen Tan Marek Babjuk Roger Li Sarah P. Psutka MD MS

Navigating clinical complex case in bladder cancer: Enbloc vs piece meal. 🔪 vs 🍰

Used a complex case to highlight key considerations in the ongoing en bloc 🧱 vs conventional TURBT 🧩 debate. Expert insights from Jeremy Teoh & David D'Andrea, panel francesco soria & Dr. Giovanni E Cacciamani MD MSc FEBU 🇮🇹🇺🇸🇪🇺 and chair Giorgio I. Russo 🩺